IDEX (IEX) Could Be 7% Below Fair Value As Earnings Near

IDEX (IEX) is back in focus as investors look ahead to its June 2026 earnings report, with expectations for higher earnings and revenue, although recently reduced profit forecasts are tempering confidence.

See our latest analysis for IDEX.

The IDEX share price has eased in the very short term, with a 1-day share price return that declined 0.42% and a 7-day share price return down 2.94%, but the picture is more constructive over longer periods, including a 90-day share price return of 8.54%, a year to date share price return of 24.10%, and a 1-year total shareholder return of 22.79%. This suggests momentum has been building ahead of the earnings update.

If the setup around IDEX has you thinking about what else is moving, this is a good time to broaden your watchlist and check out 17 top founder-led companies

IDEX shares have already moved higher over the past year, yet the stock still trades below the average analyst price target and an estimated intrinsic value. Has most of the upside been used, or is the valuation still leaving room?

Most Popular Narrative: 6.7% Undervalued

The most followed narrative on IDEX puts fair value at $238.29 per share, above the last close of $222.22, and frames the stock as modestly undervalued using an 8.61% discount rate.

Continued emphasis on international expansion and the adaptation of existing technologies for new applications in rapidly growing markets, like pharmaceutical and data centers, is likely to increase revenues and potentially improve net margins through higher-margin solutions.

Read the complete narrative.

Want to see what this expansion story really assumes? The narrative leans on steady revenue compounding, firmer margins, and a premium earnings multiple. The exact mix of those ingredients is what drives that $238.29 fair value call.

Result: Fair Value of $238.29 (UNDERVALUED)

Have a read of the narrative in full and understand what's behind the forecasts.

However, the IDEX story also depends on tariff impacts and pressure in sectors like semiconductors and agriculture not weighing more heavily on revenue and margins than expected.

Find out about the key risks to this IDEX narrative.

Next Steps

If the mixed tone around IDEX has you undecided, take a closer look at the details and form your own view, starting with the 3 key rewards.

Looking for more investment ideas beyond IDEX?

If you like the setup around IDEX, do not stop there. Widen your opportunity set and see what other stocks could strengthen your portfolio.

• Spot potential bargains early by checking out screener containing 20 high quality undiscovered gems that combine solid fundamentals with lower market attention.
• Strengthen the core of your holdings by reviewing solid balance sheet and fundamentals stocks screener (48 results) that emphasize resilient finances and dependable operations.
• Reduce portfolio stress by considering 79 resilient stocks with low risk scores that score well on stability while still offering room for growth.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com